Literature DB >> 15807825

Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre.

Thanh T Nguyen1, Trevor Gin, Kathy Nicholls, Michael Low, Jason Galanos, Andrew Crawford.   

Abstract

BACKGROUND: Fabry disease is a rare X-linked inborn error of glycosphingolipid metabolism. The aim of this study was to document the ophthalmological manifestations of patients attending the Royal Melbourne Hospital Fabry disease treatment centre.
METHODS: Patients at the treatment centre had full ophthalmological examination performed. This included best corrected visual acuity, ocular motility examination and examination of the adnexae. Patients also underwent slit-lamp examination looking for the presence of features of Fabry disease, particularly examining the bulbar conjunctiva, cornea, lens and fundus.
RESULTS: Thirty-four hemizygous male and 32 heterozygous female patients were recruited. The mean age of the hemizygous male patients was 37.7 years (range 18-57 years). The mean age of the heterozygous female patients was 34.6 years (range 1-78 years). Visual acuity was not affected. 97.1% of the hemizygotes and 78.1% of the heterozygotes had vascular abnormalities of the bulbar conjunctiva. Cornea verticillata was noted in 94.1% of the hemizygotes and 71.9% of the heterozygotes. 41.2% of the hemizygotes and 9.4% of the heterozygotes had anterior cataract formation. Posterior lens opacities were observed in 11.8% of the hemizygotes and none of the heterozygotes. Retinal vascular tortuosity was observed in 76.5% of the hemizygotes and 18.8% of the heterozygotes.
CONCLUSION: Conjunctival vascular tortuosity was the most common manifestation in this series. Conjunctival and retinal vessel tortuosity, and corneal verticillata are frequently observed in Fabry disease. The incidence of lenticular changes is not consistently reported, but in this series and many others, it is much less common than that of corneal, conjunctival and retinal changes.

Entities:  

Mesh:

Year:  2005        PMID: 15807825     DOI: 10.1111/j.1442-9071.2005.00990.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  18 in total

1.  Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey.

Authors:  Andrea Sodi; Alexander S Ioannidis; Atul Mehta; Clare Davey; Michael Beck; Suzanne Pitz
Journal:  Br J Ophthalmol       Date:  2006-09-14       Impact factor: 4.638

2.  Fabry disease in latin america: data from the fabry registry.

Authors:  J Villalobos; J M Politei; A M Martins; G Cabrera; H Amartino; R Lemay; S Ospina; S Suarez Ordoñez; C Varas
Journal:  JIMD Rep       Date:  2012-07-06

3.  Confocal laser-scanning microscopy allows differentiation between Fabry disease and amiodarone-induced keratopathy.

Authors:  Joanna Wasielica-Poslednik; Norbert Pfeiffer; Jörg Reinke; Susanne Pitz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-07-01       Impact factor: 3.117

4.  [Anterior segment findings with far-reaching consequences].

Authors:  V Besgen; P Seipelt; Y Wenner
Journal:  Ophthalmologe       Date:  2016-10       Impact factor: 1.059

5.  Assessment of corneal topographic, tomographic, densitometric, and biomechanical properties of Fabry patients with ocular manifestations.

Authors:  Veysel Cankurtaran; Kemal Tekin; Ayse Idil Cakmak; Merve Inanc; Faruk Hilmi Turgut
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-01-08       Impact factor: 3.117

6.  Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease.

Authors:  D Marchesan; T M Cox; P B Deegan
Journal:  J Inherit Metab Dis       Date:  2012-03-24       Impact factor: 4.982

7.  Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement.

Authors:  Raphael Schiffmann; Amy Rapkiewicz; Mones Abu-Asab; Markus Ries; Hasan Askari; Maria Tsokos; Martha Quezado
Journal:  Virchows Arch       Date:  2005-11-29       Impact factor: 4.064

8.  Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry mutation (IVS4 + 919G→A).

Authors:  Hsiang-Yu Lin; Cheng-Hung Huang; Hsiao-Chi Yu; Kah-Wai Chong; Ju-Hui Hsu; Pi-Chang Lee; Kang-Hsiang Cheng; Chuan-Chi Chiang; Huey-Jane Ho; Shuan-Pei Lin; Shih-Jen Chen; Po-Kang Lin; Dau-Ming Niu
Journal:  J Inherit Metab Dis       Date:  2010-09-07       Impact factor: 4.982

Review 9.  Fabry disease-often seen, rarely diagnosed.

Authors:  Björn Hoffmann; Ertan Mayatepek
Journal:  Dtsch Arztebl Int       Date:  2009-06-26       Impact factor: 5.594

10.  The microstructure of cornea verticillata in Fabry disease and amiodarone-induced keratopathy: a confocal laser-scanning microscopy study.

Authors:  Karen Falke; Armin Büttner; Michael Schittkowski; Oliver Stachs; Robert Kraak; Andrey Zhivov; Arndt Rolfs; Rudolf Guthoff
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-10-18       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.